Bladder cancer frequently announces itself through symptoms that patients dismiss as minor urinary issues, and that delay ...

A new DNA immunotherapy, Elenagen, doubled survival (13 to 25+ months) for tough ovarian cancers when added to chemotherapy, with fewer side effects.

Optune Pax® with the chemotherapy combination of gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in ...

Investigators reported results from the first randomized controlled trial of office-based laser photocoagulation to standard TURBT for low-grade Ta bladder tumors.

A new UCLA investigator-initiated study sponsored by the UCLA Health Jonsson Comprehensive Cancer Center has found that ...

Pfizer (PFE) stock is in focus as colorectal cancer therapy Braftovi as part of a combination regimen succeeds in a ...

This recent readout follows successful data from another combination including Braftovi in mCRC.

The FDA has approved a new, simplified monthly subcutaneous (SC) dosing schedule for amivantamab and hyaluronidase-lpuj (Rybrevant Faspro; Johnson & Johnson) for the treatment of patients with ...

The agency last December approved subcutaneous Rybrevant on a biweekly dosing schedule across all of its indications.